• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $DICE

    DICE Therapeutics Inc.

    Subscribe to $DICE
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2021

    Exchange: NASDAQ

    Recent Analyst Ratings for DICE Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    5/24/2023$38.00Equal Weight
    Wells Fargo
    5/22/2023$71.00Buy
    Canaccord Genuity
    3/31/2023$56.00Buy
    Needham
    3/1/2023Outperform
    TD Cowen
    3/1/2023Outperform
    Cowen
    11/15/2022$65.00Buy
    Guggenheim
    9/14/2022$36.00Overweight
    Cantor Fitzgerald
    9/7/2022$37.00Buy
    Stifel
    7/18/2022$40.00Buy
    H.C. Wainwright
    10/11/2021$46.00Outperform
    SVB Leerink
    See more ratings

    DICE Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • ShouTi Appoints Sharon Tetlow to Board of Directors

      ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company's board of directors. Ms. Tetlow will also serve as chair of the audit committee. "On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board," said Daniel Welch, Chairman of the Board, ShouTi. "Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee. With an outstanding track record of advising biopharmaceutical companies, Sharon's perspectiv

      3/29/22 8:00:00 AM ET
      $CBIO
      $DICE
      $VALN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • DICE Therapeutics Expands Management Team and Board of Directors

      Mary Riley, J.D., appointed as general counselLisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE's board of directors. Concurrently, Stephen Zachary, Ph.D., will be stepping down from the Company's board. "Mary, Lisa and Mittie are e

      3/28/22 4:05:00 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    DICE Therapeutics Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by DICE Therapeutics Inc.

      15-12G - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/21/23 8:00:26 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by DICE Therapeutics Inc.

      EFFECT - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/11/23 12:15:08 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by DICE Therapeutics Inc.

      S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/9/23 9:47:55 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by DICE Therapeutics Inc.

      S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/9/23 9:45:54 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by DICE Therapeutics Inc.

      S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/9/23 9:42:56 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POSASR filed by DICE Therapeutics Inc.

      POSASR - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/9/23 9:38:01 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by DICE Therapeutics Inc.

      POS AM - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/9/23 9:32:26 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DICE Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/9/23 9:26:58 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 14D9/A filed by DICE Therapeutics Inc. (Amendment)

      SC 14D9/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      8/9/23 9:20:55 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC TO-T/A filed by DICE Therapeutics Inc. (Amendment)

      SC TO-T/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      8/9/23 9:14:59 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    DICE Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on DICE Therapeutics with a new price target

      Wells Fargo initiated coverage of DICE Therapeutics with a rating of Equal Weight and set a new price target of $38.00

      5/24/23 7:49:57 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on DICE Therapeutics with a new price target

      Canaccord Genuity initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $71.00

      5/22/23 7:17:25 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on DICE Therapeutics with a new price target

      Needham initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $56.00

      3/31/23 7:20:41 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on DICE Therapeutics

      TD Cowen initiated coverage of DICE Therapeutics with a rating of Outperform

      3/1/23 8:59:49 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on DICE Therapeutics

      Cowen initiated coverage of DICE Therapeutics with a rating of Outperform

      3/1/23 7:37:50 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on DICE Therapeutics with a new price target

      Guggenheim initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $65.00

      11/15/22 7:33:01 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on DICE Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of DICE Therapeutics with a rating of Overweight and set a new price target of $36.00

      9/14/22 7:23:06 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on DICE Therapeutics with a new price target

      Stifel initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $37.00

      9/7/22 7:27:57 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on DICE Therapeutics with a new price target

      H.C. Wainwright initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $40.00

      7/18/22 7:21:27 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on DICE Therapeutics with a new price target

      SVB Leerink initiated coverage of DICE Therapeutics with a rating of Outperform and set a new price target of $46.00

      10/11/21 7:21:14 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    DICE Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Lilly Completes Acquisition of DICE Therapeutics

      INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new

      8/9/23 9:02:00 AM ET
      $DICE
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

      Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory p-value of 0.0008 DC-806 was well tolerated with an excellent safety profile across all dose groups in healthy volunteers and psoriasis patients with a robust PK profile and clear pharmacodynamic effects on two distinct biomarkers at both high and low doses of DC-806 Data supports further development of DC-806 as potential best-in-class oral agent for psoriasis; DC-806 is expected to advance into a Phase 2b clinical trial in the first half of 2023 Company to host conference cal

      10/11/22 7:00:00 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    DICE Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    DICE Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    DICE Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 4 filed by Ra Capital Management, L.P.

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 5:00:37 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Tetlow Sharon returned 49,841 shares to the company, closing all direct ownership in the company

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:38:19 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Simson Jake

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:36:43 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Scopa James Paul returned 40,921 shares to the company, closing all direct ownership in the company

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:33:20 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Robertson Scott M. returned 198,000 shares to the company, closing all direct ownership in the company

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:31:23 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Scheller Richard H returned 8,427 shares to the company, closing all direct ownership in the company

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:29:13 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Timothy Lu returned 152,285 shares to the company, closing all direct ownership in the company

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:26:55 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Judice Kevin returned 799,685 shares to the company, closing all direct ownership in the company

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:25:16 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Jacobsen John R. returned 147,497 shares to the company, closing all direct ownership in the company

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:23:22 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Doyle Mittie

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:21:24 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      8/9/23 5:00:12 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13G/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      7/10/23 10:20:11 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      6/23/23 5:10:56 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      6/22/23 4:32:29 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      6/21/23 5:00:23 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      3/29/23 5:14:16 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DICE Therapeutics Inc.

      SC 13G - DICE Therapeutics, Inc. (0001645569) (Subject)

      2/14/23 12:38:17 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DICE Therapeutics Inc.

      SC 13G - DICE Therapeutics, Inc. (0001645569) (Subject)

      2/14/23 9:32:16 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DICE Therapeutics Inc.

      SC 13G - DICE Therapeutics, Inc. (0001645569) (Subject)

      2/13/23 2:27:38 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13G/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      2/9/23 9:59:38 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly Completes Acquisition of DICE Therapeutics

      INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new

      8/9/23 9:02:00 AM ET
      $DICE
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly Announces Extension of Tender Offer to Acquire DICE

      INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ:DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire one minute past 11:59 p.m., Eastern time, on July 28, 2023, has been extended until one minute past 11:59 p.m., Eastern time, on Aug. 8, 2023, unless the tender offer is further extended or earlier terminated. The proposed acquisition is expected to close in the third q

      7/25/23 6:55:00 AM ET
      $DICE
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of BG, KDNY, QUOT, and DICE

      NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE:BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock. If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-m

      6/24/23 8:11:00 PM ET
      $BG
      $DICE
      $KDNY
      $QUOT
      Packaged Foods
      Consumer Staples
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

      INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and DICE Therapeutics, Inc. (NASDAQ:DICE) today announced a definitive agreement for Lilly to acquire DICE. DICE is a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "In combination with its novel technology and expertise in drug discovery, DICE's talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases," sai

      6/20/23 6:44:34 AM ET
      $DICE
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023

      SOUTH SAN FRANCISCO, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced that management will host a research & development (R&D) day on Tuesday, June 20, 2023 from 12:00 p.m. – 2:30 p.m. ET in New York, NY. The event will highlight progress on DICE's clinical-stage and discovery programs as well as key aspects of the company's DELSCAPE platform. A live and archived webcast of the R&D Day will be accessible under "News & Events" in the Investor

      6/13/23 4:05:57 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

      First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasisTopline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy volunteers expected in 2H 2023Strong financial position with $554.5 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chr

      5/11/23 4:05:33 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced management will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 3:00 p.m. PT / 6:00 p.m. ET. A live and archived webcast of the fireside chat will be accessible under "News & Events" in the Investors section of the company's website for 90 days after the event. About DICE Therapeutics, Inc.DICE Thera

      5/3/23 4:05:54 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

      SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 4:00 p.m. ET. A live and archived webcast of the fireside chat will be accessible under "News & Events" in the Investors section of the company's website for 90 days after the event. About DICE Therapeutics, Inc.DICE Th

      3/23/23 4:05:27 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

      IND application for DICE's lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023First participants dosed in Phase 1 clinical trial of second oral IL-17 antagonist DC-853; topline data in healthy volunteers expected in 2H 2023Ended 2022 with $574.2 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology pla

      3/15/23 4:05:26 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

      SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that data from its Phase 1 proof-of-concept clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17, will be presented in a late-breaking oral session at the 2023 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 17-21 in New Orleans, LA. Details of the presentation are as follows: Title: DC-806, an ora

      3/1/23 4:05:47 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care